データなし
データなし
データなし
データなし
データなし
Global Digital Therapeutics Market Report 2021: COVID-19 Impacts, Changes and Growth to 2025 & 2030 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Digital Therapeutics Global Market Report 2021: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering. The global digital therapeu
Businesswire2021/11/02 10:36 ET
7 Healthcare Stocks to Add to Your Portfolio
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthcare stocks could take over from energy stocks as top dog during this defensive cycle as yields move higher and tech stocks lose value. The post 7 Healthcare Stocks to Add to Your Portfolio appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar
InvestorPlace2021/10/06 14:21 ET
木材姉重鎮の遠隔医療の先駆者:価格設定モデルは賢明だが、なぜ保険を販売するか
Teladocはインターネット遠隔医療の草分けです。同社の強みは、米国市場の約三割のシェア、自社で構成される医師チームによる相対的にコントロールできるコスト、競合他社に比べるとより安い製品です。
市值風雲APP2021/04/22 01:23 ET
Why Goldman Sachs Is Waiting For Teladoc's Merger Story To Unfold
Teladoc Health Inc’s (NYSE: TDOC) acquisition of Livongo Health (NASDAQ: LVGO) was completed on Oct. 30 and has yet to generate impressive growth, according to Goldman Sachs. The Teladoc Health Analy
Benzinga Staff Writer2020/12/03 22:57 ET
Livongo Health Q3 Adj. EPS $0.16 Beats $0.05 Estimate, Sales $106.10M Beat $98.80M Estimate
Livongo Health (NASDAQ:LVGO) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.05 by 220 percent. This is a 420 percent increase over losses of $(0.05) per
Benzinga Real-time News2020/10/28 16:28 ET
Livongo Health Cut to Neutral From Overweight by Piper Sandler
DJ Livongo Health Cut to Neutral From Overweight by Piper Sandler Ratings actions from Benzinga: https://www.benzinga.com/stock/LVGO/ratings (END) Dow Jones Newswires October 28, 2020 05:30
Dow Jones Newswires2020/10/28 05:30 ET
データなし
データなし
Johnnie Worker : I mean buying Figma is not a bad idea, since you dont need to play around with a strong competitor and can monopolize the market.
But seriously, the premium $アドビ (ADBE.US)$paid is way too much!
1) Paying 50x PS is insane, the PS ratio of Adobe itself is only 8.4
2) Figma's valuation was just $10 Billion back in June 2021, when the market was literally crazy, and it's supposed to drop further to like $5 bcz of the current bear market. So Adobe paid 4 times! The reason is probably due to Microsoft's potential offer, and Adobe is afraid.
3)The cash and stock of the deal is 1:1, but $10 B in cash is not a penny, enough to give so much pressure on Adobe's operation, especially during its downtrend period giving that the earnings miss the estimates
Shahram Sarooj2 : Yes
sgmic66 : k
lightfoot : 20 billion is much capital outflow. Will the benefits of this merger be recognized quickly as an assets or more costs to implement. it could drag down the stock price. investors look for positive signs but later could prove very equitable for all.
PaAg1378 : M&A is a business decision akin to investors deciding which equities to acquire. Boon or bane really hinges on the accuracy of the calculated risks and profitabilities which in turn are always dependent on macro and micro determinants in the economy, market, industry, stakeholders and organization.
I will like to see Mastercard and Paypal together
もっとコメントを見る...